

Catarina Goulão catarina.goulao@tse-fr.eu

TSE, M2 EEE

Health Econometrics January 2024

I. Presentation

This is 15-hour course that spans the second semester (5 weeks). Lectures will take place on Monday 9h30-11h and Friday 11h-12h30.

The main objective is to introduce students to some of the main policy challenges and economic problems of the health care sector. For each addressed topic, I will start by exposing the economic tools and frameworks of analysis that highlight the economic mechanisms. These will then be illustrated using the most leading research applications to health care, mainly in the context of developed countries.

II. Course Requirements

Students will be evaluated on the basis of a written paper. Work in pairs. There is not a specific content of the paper but you should get my former approval. It can be a referee report of a working paper, a literature review, a research proposal. The aim is that students apply their economic knowledge and analysis to a health economics question.

The paper will have a maximum length of 10 pages, 11 fontsize, 1.5 interline space. Annexes and references, included. It will be evaluated according to the style and the contents:

1. Style (5/20 points)

- Requirements compliance: overall length, title, sections, table of contents, references, etc. (2.5 points)
- Quality of presentation: spelling, layout, graphs/figures/tables (if applicable) (2.5 points)
- 2. Contents (15/20 points)
 - Originality and ambition of the subject (3 points)
 - Literature review: context and objective; precision in presenting the economic dimension. (4 points)
 - Implementation and methods: presentation of the proposed methods, relevance and justification of the strategy adopted to address the objective. (4 points) Critical appraisal, understanding of the topic, reasoning mistakes. (4 points)



III. Outline

- 1. Introduction [CM1].
- 2. Health and health behaviours [CM2-CM4].

2.1. Health

Clever use of plain data:

Currie, J. and Schwandt, H., (2016). "Mortality Inequality: The Good News from a County-Level Approach", Journal of Economic Perspectives 30, 2, 29–52.

Currie, J., Schwandt, H., and, Thuilliez, J. (2019) "Pauvreté, Egalité, Mortalité: Mortality (In)Equality in France and the U.S.," Journal of Population Economics.

Baker, M., Currie, J. and Schwandt, H., (2019). "Mortality Inequality in Canada and the U.S.: Convergent or Divergent Trends, Journal of Labor Economics, 37 S2, S325–S353.

2.2. Health channels 1- Into causality, transmission

Bad and good uses of granulated data:

Jeremy Ginsberg, Matthew H. Mohebbi, Rajan S. Patel, Lynnette Brammer, Mark S. Smolinski & Larry Brilliant (2009). "Detecting influenza epidemics using search engine query data". Nature vol 457.

David Lazer, Ryan Kennedy, Gary King, Alessandro Vespignan (2014) "The Parable of Google Flu: Traps in Big Data Analysis". Science vol 343

Jayson S. Jia , Xin Lu , Yun Yuan , Ge Xu , Jianmin Jia & Nicholas A. Christakis (2020). "Population flow drives spatio-temporal distribution of COVID-19 in China". Nature vol 582.

Theresa Kuchler, Dominic Russel, Johannes Stroebel (2022). "JUE Insight: The geographic spread of COVID-19 correlates with the structure of social networks as measured by Facebook". Journal Urban Economics, vol 127

Jérôme Adda, Economic Activity and the Spread of Viral Diseases: Evidence from High Frequency Data , The Quarterly Journal of Economics, Volume 131, Issue 2, May 2016, Pages 891–941, https://doi.org/10.1093/qje/qjw005

2.2. Health channels 2- Into causality, early life determinants

Almond, D., Currie, J., Duque, V. "Childhood Circumstances and Adult Outcomes: Act II," the Journal of Economic Literature, Dec. 2018, 56 4, Dec. 2018, 1360–1446.

van den Berg, G., Lindeboom, M. and Portrait, F. (2006). "Economic Conditions Early in Life and Individual Mortality." American Economic Review, 96 (1): 290-302.

Starting with differences in differences:



van den Berg G., M. Lindeboom, and F. Portrait (2010). "Long-run longevityeffects of a nutritional shock early in life: the Dutch potato famine in 1846-47". Journal of Health Economics Volume 29, Issue 5

Going further with instrumental variables:

Van den Berg, GC. Pinger, PR. Schoch J. (2016) "Instrumental variable estimation of the causal effect of hunger early in life on health later in life". The Economic Journal 126 (591), 465–506.

3. Health care [CM5-CM6].

Patient's behavior:

Finkelstein, A., Einav, L., Oostrom, T., Ostriker, A., Williams, H. (2020) "Screening and Selection: The Case of Mammograms" *American Economic Review*, 110 (12) 3836–3870

Physicians' prescriptions:

Cutler, David, Jonathan S. Skinner, Ariel Dora Stern, and David Wennberg. 2019. "Physician Beliefs and Patient Preferences: A New Look at Regional Variation in Health Care Spending." American Economic Journal: Economic Policy, 11 (1): 192-221.

4. Health Insurance, moral hazard and adverse selection [CM7, CM8]

Einav, L. and Finkelstein, A.(2018)"Moral Hazard in Health Insurance: What We Know and How We Know It" Journal of the European Economic Association, 2018 vol 16(4), pages 957-982.

Learning from huge Experiments:

Newhouse JP. "Free for all? Lessons from the RAND Health Insurance Experiment". Cambridge, MA: Harvard University Press, 1993. ISBN 0-674-31846-3. [Paperback edition, 1996: ISBN 0-674-31914-1.

Aron-Dine, Einav, Finkelstein (2013). The RAND Health Insurance Experiment, Three Decades Later. Journal of Economic Perspectives, 197–222.

Baicker, Katherine, Sarah L. Taubman, Heidi L. Allen, Mira Bernstein, Jonathan H. Gruber, Joseph P. Newhouse, Eric C. Schneider, Bill J. Wright, Alan M. Zaslavsky, and Amy N. Finkelstein. 2013. "The Oregon Experiment – Effects of Medicaid on Clinical Outcomes." New England Journal of Medicine 368: 1713–22.

Learning from quasi-experimental policy implementation

Taubman, S., Wright, B., Bernstein, M., Gruber, J., Newhouse, JP., Allen,H., Baicker, K. and Finkelstein, A. (2012) "The Oregon Health Insurance Experiment: Evidence from the First Year", Quarterly Journal of Economics 127 (3): 10571106.

Finkelstein, A., Hendren, N. and Luttmer, E. F.P. (2019)"The Value of Medicaid: Interpreting Results from the Oregon Health Insurance Experiment" Journal of Political Economy Vol. 127 No. 6



5. Drugs. Pricing of new drugs [CM9].

Kyle, M. (2019). "The Single Market in Pharmaceuticals", Review of Industrial Organization, 55(1):111–135.

Dubois, P. and Saethre, M. (2020) "On the Effect of Parallel Trade on Manufacturers' and Retailers' Profits in the Pharmaceutical Sector", Econometrica, vol. 88, n. 6, November 2020, pp. 2503–2545.

Thomas, Lacy Glenn, "Implicit Industrial Policy: The Triumph of Britain and the Failure of France in Global Pharmaceuticals," Industrial and Corporate Change, 1994, 3 (2), 451–489.

Danzon, P.M. (2019) "Drug Pricing and Value in Oncology". In Regulatory and Economic Aspects in Oncology, Recent Results in Cancer Research, edited by Evelyn Walter, (2019), pp. 153-167

Danzon, P.M. (2018) "Differential Pricing of Pharmaceuticals: Theory, Evidence and Emerging Issues", PharmacoEconomics, 36 (12), pp. 1395-1405. 10.1007/s40273-018-0696-4

Danzon, P.M. (2018), "Affordability Challenges to Value-Based Pricing: Mass Diseases, Orphan Diseases, and Cures", Value in Health, 21, pp. 252-257.

DiMasi, J.A., Grabowski, H. G., Hansen, R. W. (2016) "Innovation in the pharmaceutical industry: New estimates of R&D costs", Journal of Health Economics, Volume 47, 2016, Pages 20–33,

6. Different health market structures [M10].

IV Miscellany

How to write nicely papers:

Alley, Michael. "The craft of Scientific writing", Springer; 4th edition (Mars 21, 2018). How to cite:

http://isites.harvard.edu/icb/icb.do?keyword = k70847&pageid = icb.page363223

Important dates

1. Lectures

Monday	9h00-11h00	MH204
Friday	11h00-12h30	MH203

2. Paper content proposal, by February 2, 2024. Send me an e-mail with subject "M2 EEE Health Econometrics".

3. Paper submission by March 31, 2024.